Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
Open Access
- 3 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Translational Psychiatry
- Vol. 10 (1), 1-17
- https://doi.org/10.1038/s41398-020-0709-x
Abstract
Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic treatment for mild-to-moderate Alzheimer’s disease (AD). Amyloid-β peptide (Aβ) generated from its precursor protein (APP) by β-secretase (or BACE1) and γ-secretase endoproteolysis. Alternative APP cleavage by α-secretase (a family of membrane-bound metalloproteases– Adamalysins) precludes the generation of toxic Aβ and yields a neuroprotective and neurotrophic secreted sAPPα fragment. Several signal transduction pathways, including protein kinase C and MAP kinase, stimulate α-secretase. We present data to suggest that rivastigmine, in addition to anticholinesterase activity, directs APP processing away from BACE1 and towards α-secretases. We treated rat neuronal PC12 cells and primary human brain (PHB) cultures with rivastigmine and the α-secretase inhibitor TAPI and assayed for levels of APP processing products and α-secretases. We subsequently treated 3×Tg (transgenic) mice with rivastigmine and harvested hippocampi to assay for levels of APP processing products. We also assayed postmortem human control, AD, and AD brains from subjects treated with rivastigmine for levels of APP metabolites. Rivastigmine dose-dependently promoted α-secretase activity by upregulating levels of ADAM-9, -10, and -17 α-secretases in PHB cultures. Co-treatment with TAPI eliminated rivastigmine-induced sAPPα elevation. Rivastigmine treatment elevated levels of sAPPα in 3×Tg mice. Consistent with these results, we also found elevated sAPPα in postmortem brain samples from AD patients treated with rivastigmine. Rivastigmine can modify the levels of several shedding proteins and directs APP processing toward the non-amyloidogenic pathway. This novel property of rivastigmine can be therapeutically exploited for disease-modifying intervention that goes beyond symptomatic treatment for AD.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG051086, P30AG010133)
- U.S. Department of Health & Human Services | NIH | National Institute on Aging
This publication has 119 references indexed in Scilit:
- Soluble Alpha-APP (sAPPalpha) Regulates CDK5 Expression and Activity in NeuronsPLOS ONE, 2013
- Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer’s diseaseTranslational Psychiatry, 2013
- MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressedBiochemical and Biophysical Research Communications, 2010
- Selective Translational Control of the Alzheimer Amyloid Precursor Protein Transcript by Iron Regulatory Protein-1Journal of Biological Chemistry, 2010
- EGCG functions through estrogen receptor‐mediated activation of ADAM10 in the promotion of non‐amyloidogenic processing of APPFEBS Letters, 2010
- ADAM-17 Is Activated by the Mitogenic Protein Kinase ERK in a Model of Kidney FibrosisThe American Journal of the Medical Sciences, 2010
- Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (Aβ) peptide in the human neuroblastoma cellsNeuroscience Letters, 2010
- A novel effect of rivastigmine on pre‐synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer’s diseaseJournal of Neurochemistry, 2010
- Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate α-secretase activityHuman Molecular Genetics, 2009
- Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's diseaseBiochemical Society Transactions, 2008